Replies to post #2033 on Filana Therapeutics Inc (FLNA)

[georgejjl]

Anavex designed and the FDA approve that design of a Phase 2b/3 trial with the inclusion criteria of subjects with a baseline MMSE score of between 20 and 28 inclusive.

Let's wait and see the inclusion criteria for the Cassava Phase 2b/3 trial. I bet that the inclusion criteria includes a baseline MMSE score of between 20 and 28 inclusive.

GOD bless,